INS and metabolic dysfunction-associated steatohepatitis: Several novel compounds, targeting different molecular events involved in the pathogenetic mechanism of NASH, including pathogenic metabolism, insulin resistance, inflammatory cell recruitment and pro-fibrogenic matrix profile, are currently in the pipeline, and while some of them failed in phase 2 or 3 clinical trials, others are providing promising results [5,42].